We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

LINX Reflux Management System Clinical Study Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00776997
Recruitment Status : Completed
First Posted : October 22, 2008
Results First Posted : November 13, 2013
Last Update Posted : December 18, 2013
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Gastroesophageal Reflux
Intervention: Device: Magnetic Sphincter Augmentation

  Participant Flow

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
LINX System All subjects are treated with the LINX System during a laparoscopic surgical procedure. Subjects serve as their own control. Baseline measurements are compared to post-implant measurements.

Baseline Measures
   LINX System 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   90 
>=65 years   10 
[Units: Years]
Mean (Standard Deviation)
 50.4  (12.4) 
[Units: Participants]
Female   48 
Male   52 
Region of Enrollment 
[Units: Participants]
United States   96 
Netherlands   4 
Total percentage of monitoring time esophageal pH <4 [1] 
[Units: Percent of time pH<4]
Mean (Standard Deviation)
 11.6  (4.7) 
[1] At baseline, all subjects were evaluated with esophageal pH monitoring with GERD medications discontinued for at least 7 days using the BRAVO System
Gastroesophageal Reflux Disease-Health-Related Quality of Life (GERD-HRQL) total score [1] 
[Units: Total Score]
Mean (Standard Deviation)
 26.6  (6.6) 

The GERD-HRQL scale was administered at baseline with GERD medications discontinued for at least seven days. GERD-HRQL scale objectively quantifies symptom severity. The GERD-HRQL scale consists of 10 questions with the following Responses Scale:

0 = No Symptoms

  1. = Symptoms noticeable, but not bothersome
  2. = Symptoms noticeable and bothersome, but not every day
  3. = Symptoms bothersome every day
  4. = Symptoms affect daily activities
  5. = Symptoms are incapacitating, unable to do daily activities

The worst possible score is 50 based on a response of "5" to all 10 questions.

Use of daily proton-pump inhibitors (PPIs) [1] 
[Units: Participants]
[1] At time of enrollment, all medications used by a subject were documented.
Years of proton-pump inhibitor use 
[Units: Years]
Mean (Standard Deviation)
 6.3  (4.8) 

  Outcome Measures

1.  Primary:   Rate of Occurrence for Device and Procedure Related Serious Adverse Events (SAEs).   [ Time Frame: through 24 months ]

2.  Primary:   Normalization of Esophageal Acid Exposure Time or Reduced Total Acid Exposure Time of at Least 50% Compared to the Subject's Baseline Measurement by Esophageal pH Testing.   [ Time Frame: 12 Months ]

3.  Secondary:   At Least a 50% Reduction in Gastroesophageal Reflux Disease-Health-Related Quality of Life (GERD-HRQL) Total Score Compared to Baseline   [ Time Frame: 12 months ]

4.  Secondary:   Average Daily Proton-pump Inhibitor (PPI) Dosage Reduced by at Least 50% Compared to Baseline   [ Time Frame: 12 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Amy Derosier, VP of Clinical Affairs
Organization: Torax Medical
phone: 651-361-8900
e-mail: aderosier@toraxmedical.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Torax Medical Incorporated
ClinicalTrials.gov Identifier: NCT00776997     History of Changes
Other Study ID Numbers: 1802
First Submitted: October 20, 2008
First Posted: October 22, 2008
Results First Submitted: April 25, 2012
Results First Posted: November 13, 2013
Last Update Posted: December 18, 2013